Navigation Links
Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousands of Women
Date:12/18/2007

Benefits of Arimidex (anastrozole) over tamoxifen at preventing all forms of breast cancer recurrence increase over time - even four years after

treatment ends

SAN ANTONIO, Dec. 14 /PRNewswire/ -- New data from ATAC*, one of the world's largest and longest-running studies in postmenopausal women with early breast cancer, reinforce that anastrozole can help many more women live cancer-free, for longer. For the first time, anastrozole has been shown to be the only treatment of its type to be increasingly better than tamoxifen in preventing tumours from returning.(1),(2) If cancer returns, women are much more likely to die - therefore, preventing breast cancer from returning ("recurrence") is key to saving lives.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/astrazeneca/30949/

The landmark results - presented today at the prestigious annual San Antonio Breast Cancer Symposium (SABCS), USA and also published online in The Lancet Oncology - show that even four years after a woman's treatment ends, the protective effect of anastrozole in reducing the risk of hormone-sensitive early breast cancer from returning continues to increase. Overall, women in the ATAC trial taking anastrozole were 24% less likely to have their cancer come back, compared with those taking tamoxifen.(1),(2) This demonstrates the long-term impact of treatment decisions made at diagnosis and confirms the importance of starting treatment with anastrozole to help more women beat this devastating disease. Breast cancer currently affects 1.1 million women worldwide per year 3 and hormone-sensitive early disease accounts for around 75% of all cases of breast cancer in postmenopausal women.(4)

Presenting the data at SABCS, Professor John Forbes, Newcastle Mater Misericordiae Hospital, Australia commented: "Preventing recurrence i
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Tapestry Reports Second Quarter 2007 Results
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- The escalation ... proteins, is placing renewed emphasis on alternate delivery ... as a number of factors are converging to ... makers and their delivery device partners . These ... conditions, the growing trend toward self-administration for chronic ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 ... in both dose groups. The primary endpoint assessed the ... Consistent with data reported in previous trials, the most ... Full results will be presented at an upcoming medical ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... April 17, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. ... conducted Phase 2 clinical trials,of GVAX immunotherapy ... patients with advanced prostate cancer from these,studies ... responses to a broad array of prostate ...
... A 9-month, randomized,double-blind, parallel-group Phase II study of ... given daily to the currently,approved COPAXONE(R) 20 mg ... disease activity as measured by magnetic,resonance images (MRI) ... mg experienced a reduced mean on-trial relapse rate,of ...
Cached Medicine Technology:Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 2Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 3Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 2Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 3Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 5
(Date:5/19/2013)... (PRWEB) May 19, 2013 Passages Malibu, ... treatment center, has announced this week the launch of ... the brands’ social media channels. “We are always ... treatment community and to get feedback regarding sobriety, what’s ... CEO and co-founder of the Passages Addiction Treatment ...
(Date:5/19/2013)... 19, 2013 The AMTC team will be ... Columbus Georgia Convention & Trade Center on June 1st. Professionals ... AMTC auditions are free of charge. , Actors, Models and ... hundreds of successful artists and grads like Caitlin Kinney - ... Tombolini , Chris Young - on his Liquid Neon 2013 ...
(Date:5/19/2013)... May 19, 2013 The legal team ... YazSideEffects.com in a concerted effort to connect women and ... birth control drugs Yaz, Yasmin & Ocella with the ... of information on the notorious birth control drugs as ... Pharmaceuticals. , Yaz, Yasmin & Ocella were very ...
(Date:5/18/2013)... 19, 2013 In “Cooking with Spirits for ... , author Janet Hall Svisdahl’s new cookbook, readers are transported ... to make even the pickiest eater drool. “I dedicate this ... she explains. , Found within the 364 pages of ... of delicious recipes, from fast and simple to gourmet. Each ...
(Date:5/18/2013)... 19, 2013) Each year, the American Gastroenterological ... contributions and achievements in gastroenterology through its esteemed ... distinguished and talented individuals who work tirelessly to ... we are pleased to announce the 2013 recognition ... colleagues for their tremendous contributions to our field," ...
Breaking Medicine News(10 mins):Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:Actors, Models and Talent for Christ Hosting Auditions in Columbus, GA June 1st in Search of Local Talent 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 3Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 5
... , MOUNTAIN VIEW, CA (October 25, 2011) ... the first-time discovery of the potentially protective nature of ... to be protective against a high-risk leucine-rich repeat kinase ... The LRRK2 gene is recognized as a significant risk ...
... of blood proteins can predict which patients with the progressive ... at least five years or to die within two years, ... and Centocor R&D. The findings, published online last week in ... , could help doctors determine those patients in imminent ...
... TUESDAY, Oct. 25 (HealthDay News) -- Training parents in ... conduct of preschool children with symptoms of attention-deficit/hyperactivity disorder ... also found insufficient evidence to support the use of ... age, but two drugs are generally safe and effective ...
... -- Teens who don,t get enough sleep may find themselves putting ... for obesity, new research suggests. In the study, researchers surveyed ... and found that the average sleep time on weekdays was 6 ... females. The average sleep time on weekends was 9 hours 10 ...
... supplements eaten for four to six weeks prior to prostate ... -- the number of rapidly dividing cells -- in ... diet. Done by researchers at UCLA,s Jonsson Comprehensive Cancer ... the low-fat, fish oil supplement diet were able to change ...
... new study in the Journal of Bone and Joint ... lumbar disc symptoms were significantly worse if the patients had ... to those who had symptoms for six months or less. ... satisfaction. "Patients often ask their physicians whether ...
Cached Medicine News:Health News:23andMe discovers genetic variant that may protect those at risk for Parkinson's disease 2Health News:Blood proteins predict survival in idiopathic pulmonary fibrosis, Pitt-led team says 2Health News:Parental Training May Benefit ADHD Kids Under 6: Report 2Health News:Sleepy Teens More Prone to Weight Gain: Study 2Health News:You are what you eat: Low fat diet with fish oil slowed growth of human prostate cancer cells 2Health News:You are what you eat: Low fat diet with fish oil slowed growth of human prostate cancer cells 3Health News:You are what you eat: Low fat diet with fish oil slowed growth of human prostate cancer cells 4Health News:Surgical treatment within six months of lumbar disc herniation 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: